- Efficacy and Safety of Albendazole 400 mg for 30 Days in
- 2 Adults Patients with Low Loa loa Microfilaremia: A Non-
- 3 Inferiority Randomized Controlled Trial Compared to
- 4 Ivermectin

8

12

- 6 Albendazole 400 mg for 30 days in Adult Patients with
- 7 Low Loa loa Microfilaremia
- 9 Luccheri Ndong Akomezoghe^{1,2}, Noé Patrick M'Bondoukwé^{1,2,3}, Denise Patricia Mawili Mboumba^{1,2,3}, Jacques
- Mari Ndong Ngomo^{1,2,3}, Moutombi Ditombi Bridy Chesli^{1,2,3}, Hadry Roger Sibi Matotou^{1,3}, Valentin Migueba^{1,3},
- 11 Marielle Karine Bouyou Akotet^{1,2,3*}
- 13 ¹ Department of Parasitology-Mycology-Tropical Medicine, Faculty of Medicine, Université des Sciences de la
- 14 Santé, BP 4009, Libreville Gabon
- ² Unité Mixte de Recherche sur les Agents Infectieux et leur Pathologie (UMRAIP), Université des Sciences de la
- 16 Santé, Owendo, Gabon
- ³ Centre de REcherche biomédicale en pathogènes Infectieux et Pathologies Associées (CREIPA), Libreville,
- 18 Gabon

19

22

- 20 *Corresponding author
- Email: <u>mariellebouyou@gmail.com</u> (MKBA)

Abstract

23

24

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

Background

25 Loa loa infection is endemic in central African countries like Gabon and in West Africa. Treatment typically

involves the use of ivermectin and albendazole, with albendazole often used to reduce microfilaremia in

individuals with high microfilaremia before administering ivermectin. This study aims to evaluate the efficacy and

safety of albendazole in patients with low microfilaremia.

Methodology and principal findings

The study was conducted from November 7 to April 1 across 31 villages in the Woleu-Ntem province of northern

Gabon. Following a questionnaire, venous blood was collected in EDTA tubes for Loa loa diagnosis. Eligible

individuals were randomized into two treatment groups and followed for 30 days. One group received daily

albendazole tablets (400 mg), while the other received a single dose of ivermectin (200µg/kg). The study reported

a 33.0% prevalence of Loa loa infection in northern Gabon. In the per-protocol analysis, the mean microfilaremia

decreased significantly by 82.3% and 90.4% in the ALB and IVM groups, respectively (p< 0.001). The risk

difference between the treatments was 8.1% [95% CI: 16.8; -0.6%]. For the intention-to-treat analysis, the mean

microfilaremia decreased significantly by 82.4% and 90.8% in the ALB and IVM groups, respectively (p<0.001),

with a risk difference of 8.4% [95% CI: 16.2; 0.6%]. Eosinophil rates decreased by day 30 in both groups, though

not significantly different (p>0.05).

Conclusions/Significance

The prevalence of Loa loa infection (33.05%) is notably high in northern Gabon. Albendazole demonstrated

microfilaricidal activity in individuals with low Loa loa microfilaremia. However, its efficacy appears inferior to

that of ivermectin and seems to diminish at very low microfilarial loads.

Author summary

Loa loa infection is endemic in central African countries, including Gabon, and across West Africa. Despite the

absence of specific treatments developed for Loa loa, current therapeutic approaches predominantly rely on

diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB). Although ALB is more readily available,

it is typically reserved for patients with high microfilaremia due to potential severe adverse effects following treatment with IVM. This study aimed to evaluate the efficacy and safety of ALB as an alternative treatment for patients with low microfilaremia compared to IVM. The findings suggest that ALB could serve as a viable alternative for the treatment of microfilaremic loiasis. Moreover, ALB treatment demonstrated adequate clinical efficacy and safety comparable to that of IVM.

49

50

51

52

53

54

55

Introduction

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

Loiasis is a neglected filarial parasitic disease endemic to West and Central Africa [1]. It is caused by the Loa loa worm, with adult worms residing in the skin or intermuscular fascia and microfilariae found in the blood. Over 10 million people are estimated to be carriers of this parasite [2]. Common clinical manifestations of loiasis include Calabar swelling, eyeworm, subconjunctival migration, subcutaneous crawling, and pruritus [3,4]. There are no specific drugs developed exclusively for Loa loa; however, current treatment strategies primarily rely on the use of diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB). The World Health Organization (WHO) has implemented the Community-Directed Treatment with Ivermectin to eradicate onchocerciasis and lymphatic filariasis [5,6]. However, in regions where onchocerciasis coexists with loiasis, CDTI poses a risk to individuals with Loa loa hypermicrofilaremia, defined as a parasite density higher that 8,000 microfilariae per milliliter of blood (mf/mL). Patients with this condition may experience severe and/or serious adverse events (SAEs) following IVM treatment, making areas with onchocerciasis-loiasis co-endemicity ineligible for CDTI [7,8]. In areas where onchocerciasis is hypoendemic, such as Gabon, a Test and Treat strategy is considered an alternative [9-11]. Several studies have been conducted to evaluate treatments that could safely reduce high Loa loa microfilaremia, thereby making populations eligible for IVM treatment. Different albendazole (ALB) regimens were tested using various designs. In Cameroon, administering ALB 400 mg for three days showed a reduction in microfilaremia at day 90 [12]. When patients with high Loa loa microfilaremia were given two or six doses of ALB 800 mg every two months, a decrease in microfilaremia was observed in patients receiving six doses after four months [13]. Recently in Gabon, a fiveweek regimen of ALB 400 mg showed a reduction in microfilaremia comparable to a treatment with ALB 400 mg for three weeks coupled with IVM [14]. Since the conclusion of the onchocerciasis control program activities in Gabon, IVM is not readily accessible to physicians and their patients. On one hand, these studies highlight the microfilaricidal effect of ALB; on the other hand, they underscore the lack of a standardized protocol for treating microfilaremic loiasis. A significant body of research suggests that loiasis should be regarded as a major health issue [15,16]. Most loiasis patients have low microfilaremia (< 8000 mf/mL) and reside in rural areas [17,18]. In these regions, rural communities primarily access ALB through local dispensaries, which are their main healthcare facilities. The local populations primarily engage in agriculture, fishing and hunting, which generally do not provide substantial income. Clinically, low or absent microfilaremia is often associated with frequent symptoms such as Calabar swellings [4]. It would be beneficial for these populations to assess whether ALB, an inexpensive medication,

could be used for curative purposes in patients with low microfilaremia as an alternative to IVM.

Therefore, the aim of this study was to evaluate the efficacy and safety of 400 mg dose of ALB compared to IVM

for treating infected patients in Gabon.

85

86

87

88

89

90

91

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

Material and methods

Study sites and population

92 This survey was conducted among the rural populations of Woleu-Ntem, specifically in the departments of Ntem

and Haut Ntem. Woleu-Ntem is a province located in the northern region of Gabon, a Central African country.

The province has an equatorial climate characterized by hot, humid conditions and high rainfall. It is covered with

old secondary forests and has rich and varied wildlife [19]. In Woleu-Ntem, the overall prevalence of Loa loa is

20.2%. The rural populations live along roads and rivers, with farming being their primary activity. Fishing and

hunting are also common, which increases their exposure to Chrysops bites, the vectors responsible for transmitting

Loa loa [20].

Study design

This survey is a non-inferiority randomized control trial aimed at evaluating the efficacy and safety of a 400 mg

dose of ALB taken daily for 30 days versus a single dose of IVM at 200µg/kg. The study was conducted from

November 7, 2021, to April 1, 2022, in thirty-four villages within the province of Woleu-Ntem, located in northern

Gabon. A preliminary visit was made to inform local authorities about the study's purpose. After obtaining

informed consent, participants' sociodemographic and clinical data were collected. This included information on

the study site, participant identification, age, sex, weight, height, and clinical symptoms related to loiasis, such as

worm migration into the eye, Calabar swelling, adult worm migration under the skin, and pruritus.

Inclusion criteria

Eligible participants were individuals aged 18 to 75 years who were diagnosed with Loa loa infection confirmed

by microscopy, with microfilarial counts ranging from \geq 500 to \leq 3500 mf/mL.

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

Exclusion criteria Participants were excluded if they had acute systemic illnesses, suspected allergies to benzimidazoles, or were pregnant or nursing. Blood collection and microfilaremic loiasis diagnosis Venous blood was collected in an EDTA tube for parasitological diagnosis. A 10 µL blood sample was examined directly, and the leukoconcentration technique, as described by Ho Thi Sang and Petithory, was performed [21]. Microfilaremia was quantified as the number of microfilariae per milliliter of blood (mf/mL). Absence of microfilaremia was defined as the absence of detectable parasites following both microscopic techniques. **Eosinophil count** Eosinophils were counted from a thin blood smear prepared from a 5 µl sample. The count was expressed as a percentage based on 100 white blood cells observed under a light microscope. A count of $\geq 7\%$ was considered indicative of hypereosinophilia. Randomization and treatment procedure Individuals were randomly assigned to one of two treatment groups following stratification based on three levels of Loa loa microfilaremia: 500—1500; 1501—2500; 2501—3500 mf/ml, taking into account age, gender, and the level of microfilaremia. Treatment was administered as follows: patients either received a daily dose of one tablet of ALB (400 mg) for 30 days or a single calculated dose of IVM (200µg/kg) based on the patient's weight. Both treatments were supplemented with 3 mg of antihistaminic-H2 daily for 7 days. Blood samples were collected before treatment initiation, and subsequently on days 2, 7, 14, and 30, to monitor microfilarial load and eosinophilia throughout the follow-up period.

Monitoring of clinical signs and adverse events

Adverse events were systematically evaluated throughout the study and categorized by severity: mild if they caused minimal discomfort and did not disrupt daily activities, moderate if they interfered with daily activities to a

noticeable extent, and severe if they significantly impaired the patient's ability to carry out normal daily tasks.

Efficacy assessments

137

138

139

140

141

142

144

145

146

147

148

149

150

151

153

154

155

156

157

159

160

161

143 Blood samples for direct examination (10 µL) and leukoconcentration were collected at baseline, prior to

administration of the study drug, and on days 2, 7, 14, and 30 to assess microfilarial load. Given the diurnal

periodicity of the filarial species, all efforts were made to collect blood samples between 10:00 am and 3:00 pm.

Monitoring of eosinophil count

Eosinophils were counted from a thin blood smear using 5 µl of blood. Blood smears were conducted at baseline,

prior to administration of the study drug, and on days 2, 7, 14, and 30 to assess the eosinophil levels.

Ethical considerations

152 This study was conducted as part of the PHYLECOG project funded by the EDCTP2 program under reference

TMA2019CDF-2730. The study protocol was reviewed and approved by the National Ethics Committee for

Scientific Research. Written informed consent was obtained from each participant after explaining the study

(Protocol No. 0053/2022/CNER/P/SG). The study is registered under ISRCTN14889921.

Outcomes/Endpoints

158 The primary endpoint of this study was the reduction rate of microfilaremia. Non-inferiority between a monthly

course of ALB and a single course of IVM was assessed based on the difference in reduction rates.

Treatment with ivermectin for microfilaremic loiasis typically results in rapid and sustained reduction, achieving

a reduction rate of approximately 90% after 30 days, whereas placebo generally achieves a 50% reduction [22,23].

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

To establish non-inferiority, a margin of 20% was selected using the fixed margin method, which is half the difference in reduction rates observed between ivermectin and placebo. The investigator monitored adverse events, categorizing them by type and severity. The primary safety endpoint was the occurrence of any adverse event following treatment initiation, regardless of its relationship to the study drug. The secondary safety endpoint involved tracking the evolution of eosinophil levels throughout the treatment period. Sample size Based on an expected 73% reduction in microfilaremia with ALB and a 90% reduction with IVM [22-24], and assuming a first-species risk of 5.0% and a second-species risk of 10.0%, with a non-inferiority margin of 20%, it was determined that a minimum of 18 patients per group would be required for this study. Statistical analysis Data processing was conducted using Microsoft Excel 2016, overseen by both an operator and a checker. R software version 4.3.0 was utilized for comprehensive data analysis. Statistical analyses adhered to the principles outlined in the Consort 2010 statement, employing both per-protocol and intention-to-treat methodologies [25]. The per-protocol analysis focused exclusively on patients who completed their prescribed treatment regimen. Conversely, the intention-to-treat analysis included all randomized patients, irrespective of treatment completion. Categorical data such as sex, symptoms, and adverse events were summarized as absolute values and percentages. These were compared using the proportion test, given the sample size was less than thirty, which is suitable for such analyses. Continuous variables were evaluated for normality. Variables following a normal distribution, such as age, weight, height, BMI, and microfilaremia, were presented as mean ± standard deviation. Variables not following a normal distribution, like the eosinophil rate, were presented as median [1st percentile - 3rd percentile]. The reduction rate in microfilaremia was calculated as a percentage using the formula: ((Microfilaremia at D0 -Microfilaremia during follow-up) / Microfilaremia at D0) * 100.

Comparisons of microfilaremia or eosinophil rate between different time points were conducted using Student's ttest for normally distributed variables or the Wilcoxon signed rank test for variables with non-normal distribution.

Results

189

190

191

192

193

198

Patients

194 Among the 1363 registered patients, 21 were excluded, leaving 1342 participants eligible for the study. Of these, 195 406 (30.2%) presented with Loa loa microfilaremia. Ultimately, 48 patients were enrolled, with 24 receiving ALB 196 and 24 receiving IVM. However, during the follow-up period, 10 patients withdrew their consent (Fig 1).




Fig. 1. Study flowchart. * Refusal of venipuncture; ** Long-term traveler; not visited: could not be collected at the appropriate times for microfilaremia assessment, but present at the following visit.

Demographic and baseline characteristics

200 The characteristics of the study population are summarized in Table 1. There were no significant differences 201 between the two groups of patients (p > 0.05) in terms of sex, age, weight, height, microfilaremia, and eosinophil 202 rate.

Table 1. Descriptive characteristics of the two treatment groups at the inclusion (D0)

| | ALBENDAZOLE (n=22) | IVERMECTIN (n=24) | <i>p</i> - |
|------------------------|--|--|------------|
| | n (%) | n (%) | value |
| Male | 17 (70.8) | 10 (41.7) | 0.08 |
| | Mean ± SD or | Mean ± SD or | |
| | median [1st percentile - 3rd percentile] | median [1 st percentile - 3 rd percentile] | |
| Age (years) | 49.8±12.5 | 53.0±13.6 | 0.4 |
| Weight (Kg) | 64.3±10.3 | 64.5±10.7 | 0.9 |
| Height (m) | 1.6±0.1 | 1.6±0.1 | 0.2 |
| BMI (Kg/m²) | 23.6±3.2 | 24.6±4.2 | 0.4 |
| Microfilaremia (mf/mL) | 1150 [700 - 1625] | 1350 [875 - 2000] | 0.5 |
| Eosinophil rate (%) | 16.0 [10.5 - 21.0] | 16.0 [12.5 - 25.5] | 0.5 |

204 SD: standard deviation

199

203

205

207

208

209

210

211

Per-protocol analysis 206

Efficacy of treatments on the reduction of microfilaremia

Both treatment groups showed significant reductions in mean microfilaremia from day 0 to day 30. Specifically, the ALB group exhibited a reduction of 82.3% (1339 to 237 mf/ml), while the IVM group showed a reduction of 90.4% (1395 to 134 mf/ml) (p < 0.001) (Fig 2.a). The risk difference between the two treatments was 8.1% [95% CI: 16.8; -0.6%], and the 95% confidence interval did not exceed the margin of non-inferiority.




Fig 2.a. Comparison of the albendazole and ivermectin parasitological cure rate (Per-protocol). The blue line on the chart represents the microfilaremia levels of patients treated with albendazole, while the pink line represents those treated with ivermectin.

Intention-to-treat analysis and secondary outcomes

213

214

215

216

217

218

219

220

Efficacy of treatments on the reduction of microfilaremia

The mean microfilaremia in patients from both treatment groups decreased significantly by 82.4% (1350 to 237 mf/ml) and 90.8% (1454 to 134 mf/ml) from day 0 to day 30 in the ALB and IVM groups, respectively (p < 0.001)

(Fig 2.b). The risk difference between the two treatments was 8.4% [95% CI: 16.5; 0.7%], and the 95% confidence interval did not exceed the margin of non-inferiority.

221

222

223

224

225

226

227




Fig 2.b. Comparison of the albendazole and ivermectin parasitological cure rate (Intention-to-treat). In this line chart, the blue line represents the microfilaremia levels of patients treated with albendazole, while the pink line represents those treated with ivermectin.

Incidence and progression of adverse events and symptoms during treatment

At baseline, approximately half of the patients in both groups reported symptoms: 41.7% (n=10) in the ALB group and 54.2% (n=13) in the IVM group (p=0.6). The most frequent symptom was pruritus, noted in 90.0% (n=9/10) of patients in the ALB group and 69.2% (n=9/13) in the IVM group. Over the course of follow-up, the number of patients experiencing symptoms decreased, with no patients reporting symptoms by day 30 in either group (Fig 3.a).

In terms of adverse events, a total of 10 patients (41.7%) in the ALB group and 8 patients (33.3%) in the IVM group reported adverse events by day 2 (p=0.8) (Fig 3.b). The most common adverse event in the ALB group was asthenia, reported by 80.0% (n=8/10) of those experiencing adverse events, followed by increased appetite in 20.0% (n=2/10). In the IVM group, the most common adverse events were asthenia, reported by 50.0% (n=4/8), and headache, reported by 25.0% (n=2/8) (Fig 3.b).




Fig 3.a. Changes in clinical signs and adverse events over the 30-day follow-up period. The histogram shows adult worms in the eye with blue bars, adverse events with yellow bars, Calabar swelling with red bars, crawling sensation with green bars, and pruritus with purple bars.



244

245

246

247

248

249

250

251

252

253




Fig 3.b. Changes in clinical adverse events over the 30-day follow-up period. The histogram shows appetite disorders with pink bars, asthenia with dark gold bars, diarrhea with an aquamarine bar, headache and/or vertigo with maroon bars, and nausea with a chartreuse green bar.

Efficacy of treatments on eosinophil level reduction

In both groups, eosinophil rates decreased by Day 30, although the difference was not statistically significant (p > 0.05). In the albendazole group, eosinophil rates initially increased from Day 0 to Day 2, followed by a decline across subsequent visits, reducing from a median rate of 16% to 7% (Fig 8). Conversely, in the ivermectin group, eosinophil rates remained stable from Day 0 to Day 14, with a decrease observed by Day 30 from a median rate of 16% to 4% (Fig 4).




Fig 4. Eosinophil rate progression by treatment. The blue line on the chart depicts the eosinophil rate of patients treated with albendazole, while the pink line represents those treated with ivermectin.

Time (days)

Discussion

This clinical trial represents the first comparison of a 30-day treatment regimen with ALB and IVM. The primary objective was to evaluate ALB's efficacy and safety as a potential non-inferior alternative to IVM. This is particularly relevant for landlocked rural populations who may have easier access to ALB than IVM.

In the intention-to-treat analysis of this trial, patients in both the ALB and IVM groups experienced a significant decrease in mean microfilaremia from day 0 to day 30. The reduction was more pronounced among those treated with IVM, with a risk difference of 8.6%. However, the 95% confidence interval for this difference did not reach or exceed the non-inferiority margin of 20%. These results confirm the non-inferiority of monthly ALB treatment compared to IVM.

For the per-protocol analysis, the same trend was observed. Patients' mean microfilaremia significantly decreased from day 0 to day 30 in both the ALB and IVM groups. The reduction was more pronounced in patients treated with IVM, with a risk difference of 8.1%. However, the 95% confidence interval for this risk difference did not exceed the non-inferiority margin of 20%, confirming the non-inferiority of monthly ALB treatment compared to IVM.

During the follow-up, the number of patients with symptoms decreased, and no patient exhibited any loiasis symptoms by day 30 in either group. This highlights an adequate clinical response to both treatments. However, these findings contrast with the results of the retrospective observational study by Gobbi et al., where 31.3% of patients treated with a single dose of IVM and 50% of those treated with ALB (400 mg/day) were still symptomatic after 30 days of treatment [26]. Less than half of the patients in both treatment groups experienced adverse events during the follow-up period, with asthenia being the most common in both groups. The frequency of these adverse events decreased over subsequent visits, indicating the treatments' safety, all of which were mild. Similar findings have been reported in prior studies using comparable dosages, where no participants experienced serious adverse events [26,27]. Regarding the impact of both treatments on eosinophil counts, there was no statistically significant reduction observed in either treatment group during the follow-up period. These results are consistent with Herrick et al., who found no decrease in eosinophil rates after two weeks of IVM treatment [28]. They also align with Klion et al., who reported no reduction in eosinophil rates after 21 days of ALB treatment [24]. However, despite the lack of significant decrease over the 30-day treatment period, there appeared to be a negative correlation between treatment duration and eosinophil rates. These findings suggest that monthly treatment with ALB could serve as a viable alternative for rural populations lacking easy access to IVM and limited financial resources. The study's strengths include its randomized design, prospective registration, and comprehensive analysis employing both per-protocol and intention-to-treat methods. However, the study also had its limitations. Firstly, due to the nature of the treatments, blinding was not feasible. Additionally, being a non-inferiority study focused on comparing microfilaremia reduction rates between

Conclusion

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

The prevalence of *Loa loa* infection is notably high in the investigated villages of the Woleu-Ntem province, Gabon. While IVM treatment exhibited a more pronounced microfilaricidal effect, the difference in risk between the two treatments, as indicated by the associated 95% confidence interval, did not exceed the margin of inferiority. This confirms the non-inferiority of ALB treatment. Moreover, ALB treatment demonstrated an adequate clinical response and exhibited good safety profiles similar to IVM.

treatments, it had inherent constraints in assessing other potential clinical endpoints.

Acknowledgments

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

Mawili-Mboumba, Noé Patrick M'Bondoukwé

The authors extend their sincere gratitude to all the staff at the Centre de Recherche biomédicale En pathogènes Infectieux et Pathologies Associées (CREIPA) and the Unité Mixte de Recherche sur les Agents Infectieux et leur Pathologie (UMRAIP) for their invaluable support in participant recruitment in Bitam, and for their assistance with sample analysis in both Libreville and Bitam. Special thanks are also due to the management of the Bifolossi Medical Center for generously hosting our study. We extend our appreciation to the village chiefs and other relevant authorities for their unwavering support throughout this research. Finally, heartfelt thanks to all the participants whose cooperation made this study possible. **Author contributions** Conceptualization: Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet, Noé Patrick M'Bondoukwé Data curation: Luccheri Ndong Akomezoghe, Noé Patrick M'Bondoukwé Formal analysis: Luccheri Ndong Akomezoghe, Noé Patrick M'Bondoukwé Funding acquisition: Marielle Karine Bouyou Akotet, Noé Patrick M'Bondoukwé Investigation: Luccheri Ndong Akomezoghe, Mérédith Flore Ada Mengome, Roger Hadry Sibi Matotou, Bridy Chesly Moutombi Ditombi, Valentin Migueba, Jacques Mari Ndong Ngomo, Noé Patrick M'Bondoukwé Methodology: Luccheri Ndong Akomezoghe, Denise Patricia Mawili-Mboumba, Noé Patrick M'Bondoukwé Project administration: Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet Resources: Marielle Karine Bouyou Akotet Supervision: Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet Validation: Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet Visualization: Luccheri Ndong Akomezoghe Writing-original draft: Luccheri Ndong Akomezoghe, Noé Patrick M'Bondoukwé, Denise Patricia Mawili-Mboumba Writing-review and editing: Luccheri Ndong Akomezoghe, Marielle Karine Bouyou Akotet, Denise Patricia

References

329

330 1. Wanji S, Chounna Ndongmo WP, Fombad FF, Kengne-Ouafo JA, Njouendou AJ, Longang Tchounkeu YF, et al. Impact of repeated annual community directed treatment with ivermectin 331 332 on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and 333 lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa. PLoS Negl Trop 334 Dis. 2018;12(9):1-24. 335 2. Gobbi F, Buonfrate D, Boussinesq M, Chesnais CB, Pion SD, Silva R, et al. Performance of two serodiagnostic tests for loiasis in a non-endemic area. PLoS Negl Trop Dis [Internet]. 336 337 2020;14(5):1–11. Available from: http://dx.doi.org/10.1371/journal.pntd.0008187 338 3. Bouyou Akotet MK, Owono-Medang M, Mawili-Mboumba DP, Moussavou-Boussougou MN, Nzenze Afène S, Kendjo E, et al. The relationship between microfilaraemic and 339 340 amicrofilaraemic loiasis involving co-infection with Mansonella perstans and clinical 341 symptoms in an exposed population from Gabon. J Helminthol. 2016;90(4):469–75. 342 4. Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M, 343 Kombila M. Influence of Mansonella perstans microfilaraemia on total IgE levels in Gabonese 344 patients co-infected with Loa loa. Acta Trop [Internet]. 2014;131(1):11-5. Available from: 345 http://dx.doi.org/10.1016/j.actatropica.2013.11.012 5. Cobo F. Determinants of parasite drug resistance in human lymphatic filariasis. Rev Esp 346 347 Quimioter. 2016;29(6):288-95. 348 6. Carme B, Esterre P. Filarioses. EMC - Mal Infect. 2012;9(2):1–19. 7. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M. 349 Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for 350 Loa loa infection. Lancet. 1997;350(9070):18-22. 351 352 8. Herrick JA, Egrand F, Ounoue R, Chinda G, Ontavon C, Opda J, et al. Posttreatment reactions 353 after single-dose diethylcarbamazine or ivermectin in subjects with Loa Loa infection. Clin

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

16.

Infect Dis. 2017;64(8):1017-25. 9. Ella SN, Ogoussan K, Gass K, Hundley L, Diggle PJ, Johnson O, et al. An Integrated District Mapping Strategy for Loiasis to Enable Safe Mass Treatment for Onchocerciasis in Gabon. Am J Trop Med Hyg. 2022;106(2):732-9. 10. Zouré HGM, Noma M, Tekle AH, Amazigo U V., Diggle PJ, Giorgi E, et al. The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (2) pre-control endemicity levels and estimated number infected. Parasites and Vectors. 2014;7(1):1–15. 11. Kamgno J, Nana-Djeunga HC, Pion SD, Chesnais CB, Klion AD, Mackenzie CD, et al. Operationalization of the test and not treat strategy to accelerate the elimination of onchocerciasis and lymphatic filariasis in Central Africa. Int Health. 2018;10(March):i49-53. 12. Tabi TE, Befidi-Mengue R, Nutman TB, Horton J, Folefack A, Pensia E, et al. Human loiasis in a Cameroonian village: A double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen. Am J Trop Med Hyg. 2004;71(2):211–5. Kamgno J, Nguipdop-Djomo P, Gounoue R, Téjiokem M, Kuesel AC. Effect of Two or Six 13. Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial. PLoS Negl Trop Dis. 2016;10(3):1–19. 14. Zoleko-Manego R, Kreuzmair R, Veletzky L, Ndzebe-Ndoumba W, Ekoka Mbassi D, Okwu DG, et al. Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial. PLoS Negl Trop Dis. 2023;17(8):e0011584. 15. Buell KG, Whittaker C, Chesnais CB, Jewell PD, Pion SDS, Walker M, et al. Atypical Clinical Manifestations of Loiasis and Their Relevance for Endemic Populations. Open Forum Infect Dis. 2019;6(11):1–9.

Id LV, Eberhardt KA, Hergeth J, Stelzl R, Manego RZ, Mombo-ngoma G, et al. Distinct loiasis

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

infection states and associated clinical and hematological manifestations in patients from Gabon. 2022;1–15. Mogoung-Wafo AE, Nana-Djeunga HC, Domche A, Fossuo-Thotchum F, Bopda J, 17. Mbickmen-Tchana S, et al. Prevalence and intensity of Loa loa infection over twenty-three years in three communities of the Mbalmayo health district (Central Cameroon). BMC Infect Dis. 2019;19(1):1–7. 18. Mischlinger J, Manego RZ, Id GM ngoma, Ekoka D, Id M, Hackbarth N, et al. PLOS NEGLECTED TROPICAL DISEASES Diagnostic performance of capillary and venous blood samples in the detection of Loa loa and Mansonella perstans microfilaraemia using light microscopy. 2021;1–12. 19. Ngoua-Meye-Misso RL, Sima-Obiang C, Ndong JDLC, Ndong-Atome GR, Ondo JP, Ovono Abessolo F, et al. Medicinal plants used in management of cancer and other related diseases in Woleu-Ntem province, Gabon. Eur J Integr Med [Internet]. 2019;29(May):100924. Available from: https://doi.org/10.1016/j.eujim.2019.05.010 20. Akue JP, Nkoghe D, Padilla C, Moussavou G, Moukana H, Mbou RA, et al. Epidemiology of Concomitant Infection Due to Loa loa and Mansonella perstans in Gabon. 2011;5(10). 21. Ho Thi Sang, Petithory J. Techniques for the Concentration of Microfilariae from the Blood. Bull la Soc Pathol Exot. 1963;56(2):197–206. 22. Pion SD, Tchatchueng-Mbougua JB, Chesnais CB, Kamgno J, Gardon J, Chippaux JP, et al. Effect of a single standard dose (150-200 µg/kg) of ivermectin on loa loa microfilaremia: Systematic Review and Meta-analysis. Open Forum Infect Dis. 2019;6(4):1–18. 23. Kamgno J, Pion SDS, Tejiokem MC, Twum-Danso NAY, Thylefors B, Boussinesq M. Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (~25 μg/kg) versus current standard dose (150 μg/kg). Trans R Soc Trop Med Hyg. 2007;101(8):777–85.

24. Klion AD, Massougbodji A, Horton J, Ekoué S, Lanmasso T, Ahouissou NL, et al. 404 405 Albendazole in Human Loiasis: Results of a Double-Blind, Placebo-Controlled Trial. J Infect 406 Dis. 1993;168(1):202-6. Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG. Reporting of Noninferiority and 407 25. Equivalence Randomized Trials Extension of the CONSORT 2010 Statement. 2012; 408 409 26. Gobbi F, Bottieau E, Bouchaud O, Buonfrate D, Salvador F, Rojo-Marcos G, et al. Comparison 410 of different drug regimens for the treatment of loiasis—A TropNet retrospective study. PLoS 411 Negl Trop Dis. 2018;12(11):1–11. 412 27. Bouchaud O, Matheron S, Loarec A, Dupouy Camet J, Bourée P, Godineau N, et al. Imported 413 loiasis in France: A retrospective analysis of 167 cases with comparison between sub-Saharan 414 and non sub-Saharan African patients. BMC Infect Dis. 2020;20(1):1-7. 415 28. Herrick JA, Metenou S, Makiya MA, Taylar-Williams CA, Law MA, Klion AD, et al. 416 Eosinophil-associated processes underlie differences in clinical presentation of loiasis between 417 temporary residents and those indigenous to loa-endemic areas. Clin Infect Dis. 2015;60(1):55-418 63.

419